Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Conditions: HER2/Neu Negative; Recurrent Inflammatory Breast Carcinoma; Stage IV Breast Cancer; Stage IV Inflammatory Breast Carcinoma Interventions: Biological: Ipilimumab; Other: Laboratory Biomarker Analysis; Biological: Nivolumab Sponsors: Northwestern University; Bristol-Myers Squibb; National Cancer Institute (NCI) Not yet recruiting - verified September 2016
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Breast Cancer | Breast Carcinoma | Cancer | Cancer & Oncology | Carcinoma | HER2 | Inflammatory Breast Cancer | Research | Yervoy